Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease


Punekar, YS; Sunderland, T; Hawkins, N; Lindsay, J; (2010) Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease. Value in health, 13. pp. 188-195. ISSN 1098-3015 DOI: https://doi.org/10.1111/j.1524-4733.2009.00658.x

Full text not available from this repository.

Abstract

Infliximab recently became the only biologic approved for use in pediatric patients with severe active Crohn's disease (CD).

Item Type: Article
Keywords: Cost-effectiveness, Crohn's disease, Infliximab, Pediatric, Anti-Inflammatory Agents, administration & dosage, economics, Antibodies, Monoclonal, administration & dosage, economics, Child, Cost-Benefit Analysis, Crohn Disease, drug therapy, economics, Drug Administration Schedule, Great Britain, Humans, Infliximab, Markov Chains, Quality-Adjusted Life Years, State Medicine, Treatment Outcome
Faculty and Department: Faculty of Public Health and Policy > Dept of Health Services Research and Policy
PubMed ID: 19883407
Web of Science ID: 274668300005
URI: http://researchonline.lshtm.ac.uk/id/eprint/2551686

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
117Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item